Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hess

Showing results (521-530 of 543) with videos related to

Pageof 55
Sort By:
Journal of Cellular Biochemistry|May 23, 2014
Osteoblasts protect AML cells from SDF-1-induced apoptosisKimberly N Kremer, Amel Dudakovic, Meghan E McGee-Lawrence, et al.
Iscience|December 17, 2024
Identification and development of TRPM4 antagonists to counteract neuronal excitotoxicityLars Binkle-Ladisch, Andy Pironet, Andrea Zaliani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumoursM J A de Jonge, J Verweij, A van der Gaast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2006
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumorsC Sessa, S Cresta, T Cerny, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|February 21, 2015
Epizootiology of Tacaribe serocomplex viruses (Arenaviridae) associated with neotomine rodents (Cricetidae, Neotominae) in southern CaliforniaMary Louise Milazzo, Maria N B Cajimat, Matthew R Mauldin, et al.
Journal of Hematotherapy|May 23, 1998
CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftmentS J Noga, A Seber, J M Davis, et al.
Scientific Reports|October 7, 2021
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibersAdam J Davenport, Ioana Neagoe, Nico Bräuer, et al.
ACS Chemical Biology|May 16, 2025
Discovery and Characterization of Small Molecule Inhibitors Targeting Exonuclease 1 for Homologous Recombination-Deficient Cancer TherapyYixing Wang, Jessica D Hess, Chen Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 1999
SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5M A Varney, N D Cosford, C Jachec, et al.
Bone Marrow Transplantation|December 16, 1998
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignanciesP V O'Donnell, R J Jones, G B Vogelsang, et al.
Pageof 55

Showing results (521-530 of 543) with videos related to

Sort By:
Pageof 55
Journal of Cellular Biochemistry|May 23, 2014
Osteoblasts protect AML cells from SDF-1-induced apoptosisKimberly N Kremer, Amel Dudakovic, Meghan E McGee-Lawrence, et al.
Iscience|December 17, 2024
Identification and development of TRPM4 antagonists to counteract neuronal excitotoxicityLars Binkle-Ladisch, Andy Pironet, Andrea Zaliani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2002
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumoursM J A de Jonge, J Verweij, A van der Gaast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2006
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumorsC Sessa, S Cresta, T Cerny, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|February 21, 2015
Epizootiology of Tacaribe serocomplex viruses (Arenaviridae) associated with neotomine rodents (Cricetidae, Neotominae) in southern CaliforniaMary Louise Milazzo, Maria N B Cajimat, Matthew R Mauldin, et al.
Journal of Hematotherapy|May 23, 1998
CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftmentS J Noga, A Seber, J M Davis, et al.
Scientific Reports|October 7, 2021
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibersAdam J Davenport, Ioana Neagoe, Nico Bräuer, et al.
ACS Chemical Biology|May 16, 2025
Discovery and Characterization of Small Molecule Inhibitors Targeting Exonuclease 1 for Homologous Recombination-Deficient Cancer TherapyYixing Wang, Jessica D Hess, Chen Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 1999
SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5M A Varney, N D Cosford, C Jachec, et al.
Bone Marrow Transplantation|December 16, 1998
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignanciesP V O'Donnell, R J Jones, G B Vogelsang, et al.
Pageof 55